Category: BÜHLMANN Calprotectin Assay Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis

BÜHLMANN MRP8/14 ELISA: Cypers H et al.: Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Annals of the Rheumatic Diseases. 2015.  PMID: 26698844  DOI: 10.1136/annrheumdis-2015-208025 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis

BÜHLMANN MRP8/14 ELISA: Anink J et al.: MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Research and Therapy. 2015: 17:200 PMID: 26249667  doi:  10.1186/s13075-015-0723-1 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Review of biomarkers in systemic juvenile idiopathic arthritis

BÜHLMANN MRP8/14 ELISA: Rothmund F et al.: Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. Arthritis Care Research (Hoboken). 2014: 66(6):949-55. PMID: 27411444   DOI: 10.1186/s13075-016-1069-z Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort

BÜHLMANN MRP8/14 ELISA: García-Arias M et al.: Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Molecular Diagnosis and Therapy. 2013: 17(1):49-56.  PMID: 23329363 DOI: 10.1007/s40291-013-0016-9 Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US and Canada.
Continue Reading

Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis

BÜHLMANN sCAL ELISA: Andrés Cerezo et al.: Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Research and Therapy. 2011; 13(4).  PMID: 21791097  DOI: 10.1186/ar3426 . Read Citation BÜHLMANN sCAL ELISA is for Research Use Only.  Not for use in diagnostic procedures in
Continue Reading

Ulcerative Colitis Study: Correlation of Faecal Calprotectin with Histological Nancy Index

BÜHLMANN IBDoc®: Walsh, A, Kormilitzin, A. et al. New faecal calprotectin cut-off points for remission and active disease defined by UCEIS and Nancy indices in ulcerative colitis (UC).  13th Congress of ECCO 2018, Feb 14 – 17, 2018. Vienna, Austria. Highlights from this Poster “Conclusions. An FCal <180 g/g is indicative of endoscopic and histological remission. FCal
Continue Reading

Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®

BÜHLMANN IBDoc®: Wong, A, Bourdages, R. et al. Home-based Fecal Calprotectin Testing: A Canadian User Performance Evaluation Study of IBDoc®.  CDDW 2018, Feb 09 – 11, 2018. Toronto, ON Canada. Highlights from this Publication “Conclusions. The IBDoc® test kit was understood by participants, with a majority of participants finding it easy to use, with an
Continue Reading

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: A.Kostas, S.I. Siakavellas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a
Continue Reading

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading

Analytical and Diagnostic Performance of Two Automated Fecal Calprotectin Immunoassays for Detection of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA: De Sloovere, M. et al. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease, Clin Chem Lab Med. 2017 Aug 28;55(9):1435-1446. PMID: 28076305  DOI: 10.1515/cclm-2016-0796. Highlights from this Publication ““Bühlmann assays were superior with 100 % sensitivity…”.” Read Citation BÜHLMANN fCAL® ELISA is for Research Use Only.  Not for use
Continue Reading